ArticlePediatric research2026
Protective effects of enteral acetate supplementation against brain injury in a rat model of necrotizing enterocolitis.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Case for Vinegar Ingestion.Nutrients · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNecrotizing enterocolitis (NEC) is a severe gastrointestinal disease in preterm infants, often leading to brain injury. The microbiota-gut-brain axis (MGBA) plays a key role, with short-chain fatty acids (SCFAs) emerging as potential therapeutic agents. This study explores the impact of SCFAs, particularly acetate, in mitigating NEC-related brain injury.
methodsA NEC rat model was established via overfeeding, hypoxia, and asphyxia. Intestinal injury, SCFA levels, systemic inflammation, and neuroinflammation were assessed through histology, gas chromatography-mass spectrometry, ELISA, and Western blotting. Cognitive function was evaluated using the Morris water maze test.
resultsNEC rats exhibited significantly lower levels of intestinal SCFAs, particularly acetate, compared to control rats. These reductions were accompanied by systemic inflammation, neuroinflammation and cognitive deficits. Supplementation with sodium acetate mitigated both intestinal and neuroinflammatory responses and improved cognitive function.
conclusionsAcetate depletion contributes to NEC-associated brain injury, and early acetate supplementation may offer a promising therapeutic strategy to mitigate intestinal damage, neuroinflammation, and cognitive impairment. IMPACT: Identifies acetate depletion as a key factor in NEC-related brain injury. Demonstrates that sodium acetate supplementation mitigates neuroinflammation and cognitive impairment. Expands understanding of the microbiota-gut-brain axis in NEC pathophysiology. Highlights SCFAs as potential therapeutic agents for NEC-related complications. Suggests a novel intervention strategy to improve neurodevelopmental outcomes in preterm infants.
Identifiers
41935130What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.